Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies. Operating from Manchester, with research facilities in Bradford and Salford, Incanthera Ltd was established from the University of Bradford’s Institute of Cancer Therapeutics (www.cancer.brad.ac.uk).
Incanthera is uniquely positioned to access commercially valuable patent estates and development programmes, initially from the Institute, but with a wider horizon for pipeline acquisition. The first product, and primary focus has been to bring ICT2588, a novel treatment for solid tumours, to a licensing partner. This was successfully achieved through our first commercial deal, announced in July 2017, bringing the product to Phase I clinical trial in early 2018. The provenance of Incanthera’s pipeline includes a number of UK Universities and, consequently, a heritage of world-leading scientific drug discovery.